Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PIR | O00625 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CD4 | P01730 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23213167 | 0.95 | KEAP1 (0.43) | LMNAMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23210226 | 0.89 | LMNA (0.44) | LMNAMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23210311 | 0.89 | LMNA (0.44) | LMNAMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23209991 | 0.86 | LMNA (0.48) | LMNAMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23212912 | 0.84 | KEAP1 (0.42) | LMNAMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23213647 | 0.84 | KEAP1 (0.42) | LMNAMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23213273 | 0.84 | KDM1A (0.40) | LMNAMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL23210281 | 0.83 | KDM1A (0.41) | LMNAMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL26780885 | 0.79 | LMNA (0.40) | LMNAMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4057724 | 0.78 | LMNA (0.43) | LMNAMAPTCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2024-05-02 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11485742-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2022-11-01 | — | — | US | disclosed |
| EP-4041737-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021070091-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485742-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | LMNA 4761/4885MAPT 3879/4885CYP1A2 568/4885 |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | LMNA 4761/4885MAPT 3879/4885CYP1A2 568/4885 |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | LMNA 4761/4885MAPT 3879/4885CYP1A2 568/4885 |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | LMNA 4764/4885MAPT 3906/4885CYP1A2 561/4885 |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | LMNA 4761/4885MAPT 3879/4885CYP1A2 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.